原発性胆汁性胆管炎(PBC)を患う成人日本人参加者におけるエラフィブラノールの研究 (ELONSEN)
原発性胆汁性胆管炎(PBC)の成人日本人参加者を対象としたエラフィブラノール 80 mg の有効性と安全性を調査する第 III 相非盲検単群試験
The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease.
PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis).
PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. In this study all participants will receive a daily dose of elafibranor (the study intervention).
The main aim of this study is to determine if elafibranor reduces alkaline phosphatase (ALP) and total bilirubin levels. High ALP and bilirubin levels in the blood can indicate liver disease.
There will be 4 periods in this study: A screening period (up to 10 weeks) to assess whether the participant can take part. A treatment period (52 weeks) where all eligible participants will receive elafibranor. A variable treatment extension period (2-5 years) from End Of Treatment (EOT) period up to the commercial availability of elafibranor in Japan. A follow-up period (4 weeks) where participants' health will be monitored.
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a non-invasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to approximately 6 years
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Chiba、日本
- Nippon Medical School - Chiba Hokusoh Hospital
-
Fukushima、日本
- Fukushima Medical University Hospital
-
Hiroshima、日本
- Chugoku Rosai Hospital
-
Hokkaido、日本
- Teine Keijinkai Hospital
-
Kagawa、日本
- Kagawa University Hospital
-
Kagoshima、日本
- Kagoshima University Hospital
-
Nagano、日本
- Shinshu University Hospital
-
Nagasaki、日本
- National Hospital Organization Nagasaki Medical Center
-
Nara、日本
- Nara Medical University Hospital
-
Niigata、日本
- Niigata University Medical & Dental Hospital
-
Niigata、日本
- Nagaoka Red Cross Hospital
-
Osaka、日本
- National Hospital Organization Osaka National Hospital
-
Shizuoka、日本
- Hamamatsu University Hospital
-
Tokyo、日本
- Juntendo University Hospital
-
Tokyo、日本
- Teikyo University Hospital
-
Tokyo、日本
- Tokyo Metropolitan Komagome Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Must have provided written informed consent and agree to comply with the study protocol.
- Japanese male or female participants aged 18 to 75 years inclusive at Screening Visit 1 (SV1).
- PBC diagnosis as described in the study protocol
- ALP ≥1.67×ULN (mean value based on samples collected at SV1 and SV2).
- TB ≤2×ULN at SV1 and SV2.
- Must have at least 4 available values for PBC Worst Itch Numeric Rating Scale (NRS) during each of the 7-day intervals in the 14 days prior to visit (V)1, for a total of at least 8 values for PBC Worst Itch NRS in the last 14 days prior to V1.
- Participants taking UDCA for at least 12 months (stable dose ≥3 months) prior to screening, or unable to tolerate UDCA treatment (no UDCA for ≥3 months) prior to screening (per country standard-of-care dosing).
- If on colchicine, must be on a stable dose for ≥3 months prior to screening.
- Medications for management of pruritus (for example, cholestyramine, rifampicin, naltrexone, sertraline or nalfurafine hydrochloride) must be on a stable dose for ≥3 months prior to screening.
- Participants taking statins or ezetimibe must be on a stable dose for ≥2 months prior to screening.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Exclusion Criteria
-
History or presence of other concomitant liver disease
-
Participants with known cirrhosis who have a Child-Pugh B or C classification.
-
Participants with cirrhosis with Child-Pugh A classification are allowed.
-
History or presence of clinically significant hepatic decompensation,
-
Medical conditions that may cause non-hepatic increases in ALP (for example, Paget's disease) or which may diminish life expectancy to <2 years, including known cancers.
-
Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix.
-
Participant has a positive test for human immunodeficiency virus (HIV) Type 1 or 2 at screening, or participant is known to have tested positive for HIV.
-
Evidence of any other unstable or untreated clinically significant immunological, endocrine, haematologic, gastrointestinal, neurological, or psychiatric disease as evaluated by the investigator; other clinically significant medical conditions that are not well controlled.
-
History of alcohol abuse, defined as consumption of more than 30 g pure alcohol per day for men, and more than 20 g pure alcohol per day for women, or other substance abuse within 1 year prior to SV1.
-
For female participants: known pregnancy, or has a positive serum pregnancy test, or breastfeeding.
-
Administration of the following medications are prohibited as specified below:
- 1 month prior to screening: fibrates.
- 2 months prior to screening: glitazones.
- For participants with previous exposure to obeticholic acid (OCA), OCA should be discontinued 3 months prior to screening.
- 3 months prior to screening: azathioprine, cyclosporine (systemic), methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (parenteral and oral chronic administration only); potentially hepatotoxic drugs (including α-methyldopa, sodium valproate/valproic acid isoniazid, or nitrofurantoin).
- 12 months prior to screening: antibodies or immunotherapy directed against interleukins (ILs) or other cytokines or chemokines.
-
Participants who are currently participating in, plan to participate in, or have participated in an investigational drug study or medical device study containing active substance within 30 days or 5 half-lives, whichever is longer, prior to screening; for participants with previous exposure to seladelpar, seladelpar should be discontinued 3 months prior to screening.
-
Participants with previous exposure to elafibranor.
-
SV1 or SV2 value ALT and/or AST >5×ULN.
-
For participants with aminotransferases or TB >ULN at SV1, variability (between SV1 and SV2) of aminotransferases or TB >40%.
-
SV1 value albumin <3.0 g/dL.
-
Severely advanced participants according to Rotterdam criteria (TB >ULN and albumin <LLN).
-
SV1 international normalised ratio (INR) >1.3 due to altered hepatic function.
-
SV1 creatine phosphokinase (CPK) >2×ULN.
-
SV1 serum creatinine >1.5 mg/dL.
-
Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as participants with markers of kidney failure damage or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2) calculated by modification of diet in renal disease study (MDRD).
-
SV1 platelet count <150×103/μL.
-
Alpha-fetoprotein (AFP) >20 ng/mL with 4-phase liver computerised tomography (CT) or magnetic resonance imaging (MRI) imaging suggesting presence of liver cancer.
-
Known hypersensitivity to the investigational product or to any of the formulation excipients of the elafibranor tablet.
-
Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Elafibranor
Participants will take the study intervention by mouth (swallow whole) once daily |
Tablet of 80 mg |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
アルカリホスファターゼ(ALP)がULNの1.67倍未満、ALP減少が15%以上、総ビリルビン(TB)がULN以下の参加者の割合
時間枠:52週目
|
52週目
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ALPレベルを正常化した参加者の割合
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALPレベルのベースラインからの変化
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP <1.5×ULN、ALP減少≧40%、TB≦ULNの参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP<3xULN、アスパラギン酸アミノトランスフェラーゼ(AST)<2xULN、および総ビリルビン(TB)<1mg/dL(パリI基準)を有する参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP ≤1.5×ULN、AST ≤1.5×ULN、および TB ≤ULN(パリ II 基準)の参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
結核反応率が 15% の参加者の割合が変化します。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
異常な結核および/またはアルブミンが正常化した参加者の割合(ロッテルダム基準)。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
結核を有する参加者の割合 ≤0.6×ULN
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP ≤1.67×ULN および TB ≤1 mg/dL の参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
結核レベルの悪化がなかった参加者の割合
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP ≤1.67×ULN、ALP 減少 15% 以上、TB ≤ULN の参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP <1.5×ULN、ALP減少≧15%、TB≦ULNの参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ALP ≤ULN および TB ≤ULN の参加者の割合。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ビリルビンの正常化に基づく反応。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
アルブミンレベルの正常化に基づく反応。
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
ベースラインからそう痒症が悪化しなかった参加者の割合
時間枠:26週目と52週目、および研究終了まで26週間ごと(最長6年間)
|
26週目と52週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
判定された個々の臨床転帰事象が最初に発生するまでの時間
時間枠:4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
4週目、13週目、26週目、39週目、52週目、78週目、および研究終了まで26週間ごと(最長6年間)
|
|
|
空腹時血漿グルコース(FPG)レベルのベースラインからの変化
時間枠:52週目および研究終了まで26週間ごと(最長6年間)
|
52週目および研究終了まで26週間ごと(最長6年間)
|
|
|
時間0から24時間までの血漿濃度-時間曲線の下の面積: AUC0-24
時間枠:4週目時点
|
4週目時点
|
|
|
最大(ピーク)血漿薬物濃度:Cmax
時間枠:4週目時点
|
4週目時点
|
|
|
薬物投与後に最大(ピーク)血漿濃度に達するまでの時間):Tmax
時間枠:4週目時点
|
4週目時点
|
|
|
Percentage of Participants With ALP Level response
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Defined as 10%, 20% and 40% ALP reduction from baseline |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Percentage of participants with complete biochemical response
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Defined as normal ALP; TB; AST; alanine aminotransferase (ALT); albumin; and INR. |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in PBC risk scores based in Global PBC Study Group (GLOBE) score
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in PBC risk scores based on United Kingdom (UK)-PBC score.
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
PBC risk score developed by United Kingdom (UK)-PBC Consortium is a scoring system and the calculation is based on laboratory test measurements and upper limits of normal (ULN) for the total bilirubin (BIL12); alanine transaminase or aspartate transaminase (TA12), and alkaline phosphatase (ALP12) after at least 12 months of UDCA, and the laboratory test measurements and lower limits of normal (LLN) for the serum albumin and platelet count in the same timeframe. A high number is indicative of a worse score. |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in hepatobiliary injury and liver function
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Hepatobiliary injury and liver function will be measured by AST, ALT, gamma-glutamyl transferase (GGT), 5'nucleotidase (5' NT), total and conjugated bilirubin, albumin, INR, and ALP fractionated (hepatic). |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in lipid parameters
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Lipid parameters as measured by total cholesterol (TC), low-density lipoprotein cholesterol ( LDL-C), high-density lipoprotein cholesterol (HDL-C), calculated very low-density lipoprotein cholesterol (VLDL-C) and triglycerides (TG). |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in liver stiffness measurement (LSM)
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Assessed by vibration-controlled transient elastography (VCTE) using Fibroscan® |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in pruritus
時間枠:At Week 26, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Based on PBC Worst Itch Numeric Rating Scale (NRS) score in participants with baseline PBC Worst Itch NRS score ≥4. |
At Week 26, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Proportion of responders in PBC Worst Itch NRS according to clinically meaningful change from baseline
時間枠:At Week 26 and at Week 52 and every 26 weeks until the end of study (up to 6 years)
|
At least 30% reduction; and one point, two points or three points decrease in score in participants with a baseline NRS score ≥4. |
At Week 26 and at Week 52 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in 5D-Itch scale
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Questionnaire that assesses symptoms in terms of 5 domains: degree, duration, direction, disability and distribution. Participants rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a scores
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
PROMIS Fatigue Short Form 7a scores consists of 7 items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 to 5. Scores can range from 7 to 35, with higher scores indicating greater fatigue. |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in Epworth Sleepiness Scale (ESS).
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in different situations commonly encountered in daily life (each question can be scored from 0 to 3 points; '0' indicates no sleepiness, '3' indicates significant sleepiness). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0-24 points). |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in PBC-40.
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
40-item questionnaire that assesses symptoms across 6 domains: fatigue, emotional and social, cognitive function, general symptoms and itch. Participants respond on a verbal response scale, depending on the section options range from 'never' / 'not at all' / 'strongly disagree' to 'always' / 'very much' / 'strongly agree'. Six items (3/3 in the itch domain, 2/10 in the social domain, and 1/7 in the general symptoms domain) also include a 'does not apply' option. A score for each domain is provided (but a total score is not calculated), with each verbal response scale correlating to a score of 1 to 5 per item (0 to 5 on items with a 'does not apply' option) with 5 being the most affected (greatest burden). |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in EuroQol 5-dimensional 5-level questionnaire (EQ-5D-5L)
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
Self-administered standardised questionnaire that assesses the 5-dimensions of mobility, self-care, usual activities, pain/discomfort, anxiety/depression descriptively (each dimension has 5 levels) and the overall health state via an EQ Visual Analogue Scale (VAS). |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Change from baseline in Patient Global Impression of Severity (PGI-S)
時間枠:At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
A 1-item, 5-point scale designed to assess the participant's impression of change in disease severity since the baseline visit |
At Week 4, Week 13, Week 26, Week 39, Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)
|
|
Patient Global Impression of Change (PGI-C)
時間枠:At Week 4, Week 13, Week 26, Week 39, and Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)]
|
A 1-item, 5-point scale designed to assess the participant's impression of change in disease severity since the baseline visit |
At Week 4, Week 13, Week 26, Week 39, and Week 52, Week 78 and every 26 weeks until the end of study (up to 6 years)]
|
|
Percentage of participants who experience Treatment Emergent Adverse Events (TEAEs), treatment related TEAEs, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs).
時間枠:From baseline to end of study (up to 6 years)
|
An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AESIs are AEs that may not be serious but are of special importance to a particular drug or class of drugs. |
From baseline to end of study (up to 6 years)
|
|
Percentage of participants who develop clinically significant changes from baseline in physical examination findings
時間枠:From baseline to end of study (up to 6 years)
|
Clinically significant change in physical examination findings will be reported. The clinical significance will be graded by the investigator. |
From baseline to end of study (up to 6 years)
|
|
Percentage of participants who develop clinically significant changes from baseline in vital signs
時間枠:From baseline to end of study (up to 6 years)
|
Clinically significant change in vital signs will be reported. The clinical significance will be graded by the investigator. |
From baseline to end of study (up to 6 years)
|
|
Percentage of participants with clinically significant changes in laboratory parameters (blood chemistry, hematology, liver tests, renal tests (including urinalysis).
時間枠:From baseline to end of study (up to 6 years)
|
Clinically significant change in laboratory parameters will be reported. The clinical significance will be graded by the investigator. |
From baseline to end of study (up to 6 years)
|
|
Percentage of participants who develop clinically significant changes from baseline in ECG readings
時間枠:From baseline to end of study (up to 6 years)
|
Clinically significant change in ECG readings. The clinical significance will be graded by the investigator. |
From baseline to end of study (up to 6 years)
|
|
Change from baseline in serum markers of bone turnover and in bone mineral density (hip and lumbar)
時間枠:At Week 52 and every 26 weeks until the end of study (up to 6 years)
|
Assessed by dual-energy X-ray absorptiometry (DEXA) scanning. |
At Week 52 and every 26 weeks until the end of study (up to 6 years)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Ipsen Medical, Director、Ipsen
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CLIN-60190-462
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共有時間枠
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共有アクセス基準
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。